Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release ‘Leading U.K. Medical Journal publishes a Complex Case of Severe Pan-drug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich® (Zidebactam/Cefepime, WCK 5222)’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.20 |
| Dr. Reddys Lab | 1295.00 |
| Cipla | 1322.70 |
| Zydus Lifesciences | 948.00 |
| Lupin | 2278.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: